application abstract): This proposal is to establish an ACTU with a main unit based at Tulane University Medical Center and a subunit at Louisiana state University Medical Center, both in New Orleans, with the following goals. 1) To recruit 80 or more new patients per year into ACTG sponsored Phase I, II, III protocols for the treatment of HIV infection, opportunistic infections, and neurologic complications of AIDS. 2) To use GCRC for Phase I and II clinical trials and pathogenesis-related exploratory trials of new treatments for HIV. 3) To establish support laboratories to perform protocol mandated studies in virology, pharmacology, and immunology. 4) To systematically address women's health-related issues. 5) To recruit an ethnically diverse population of patients, representative of the regional population, in order to give minority populations and women access to ACTG clinical trials. 6) To address the subjects of compliance and patient retention, including outreach programs. 7) To work with the local CAB to include local patients and their advocates in the implementation of the ACTU research agenda. Scientifically the following areas will be emphasized: 1) Phase I pharmacokinetic, drug interactions, and toxicity studies, and pilot studies of HIV pathogenesis; 2) Correlations of plasma and intracellular drug levels with changes in viral load; 3) Pathogenesis of HIV and HTLV-I/II co-infection; 4) Therapy of HIV-induced thrombocytopenia; 5) HIV neuropathy; 6) Immune resistance of HIV; 7) Mechanisms and prevention of HIV-induced apoptosis; 8) Therapy of opportunistic diseases (mainly microporidiosis and mycobacterial infections); 9) Pathogenesis and therapy of cervical dysplasia in HIV infected women

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01AI038844-04S1
Application #
6266062
Study Section
Special Emphasis Panel (SRC (82))
Program Officer
Batzold, Frederick
Project Start
1996-01-01
Project End
2002-12-31
Budget Start
1999-01-01
Budget End
2002-12-31
Support Year
4
Fiscal Year
2000
Total Cost
$656,013
Indirect Cost
Name
Tulane University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
New Orleans
State
LA
Country
United States
Zip Code
70118
Leger, Paul D; Johnson, Daniel H; Robbins, Gregory K et al. (2014) Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384. J Neurovirol 20:304-8
Kiezun, Adam; Garimella, Kiran; Do, Ron et al. (2012) Exome sequencing and the genetic basis of complex traits. Nat Genet 44:623-30
McLaren, Paul J; Ripke, Stephan; Pelak, Kimberly et al. (2012) Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. Hum Mol Genet 21:4334-47
Pasaniuc, Bogdan; Rohland, Nadin; McLaren, Paul J et al. (2012) Extremely low-coverage sequencing and imputation increases power for genome-wide association studies. Nat Genet 44:631-5
Hulgan, Todd; Robbins, Gregory K; Kalams, Spyros A et al. (2012) T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384. PLoS One 7:e43803
Ribaudo, Heather J; Benson, Constance A; Zheng, Yu et al. (2011) No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis 52:929-40
Grady, Benjamin J; Samuels, David C; Robbins, Gregory K et al. (2011) Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384. J Acquir Immune Defic Syndr 58:363-70
Grady, Benjamin J; Torstenson, Eric S; McLaren, Paul J et al. (2011) Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants. Pac Symp Biocomput :253-64
International HIV Controllers Study (see original citation for additional authors) (2010) The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330:1551-7
Ferreira, Manuel A R; Mangino, Massimo; Brumme, Chanson J et al. (2010) Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control. Am J Hum Genet 86:88-92

Showing the most recent 10 out of 18 publications